AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8048850 — intervention group
Group type: COMPARATOR
Intervention: Three-quarter Nissen fundoplication without dissection and exclusion of vagus nerves
Number of subjects: 42
Study 2903085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + cisplatin (CP)
Number of subjects: 48
Study 2903085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + doxorubicin + cisplatin (CAP)
Number of subjects: 48
Study 2903085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + 4'-epi-doxorubicin + cisplatin (CEP)
Number of subjects: 48
Study 12843342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis with recombinant pro-urokinase
Number of subjects: 154
Study 12843342 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 154
Study 30221596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day)
Number of subjects: 19114
Study 30221596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 27585746 — intervention group
Group type: EXPERIMENTAL
Intervention: NDT-Bobath method
Number of subjects: 72
Study 27585746 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF method
Number of subjects: 72
Study 23920050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical groups (FEP, ARMS, HSC)
Number of subjects: 191
Study 23920050 — intervention group
Group type: COMPARATOR
Intervention: Non-help-seeking group (NH)
Number of subjects: 191
Study 23920050 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative beliefs about self and others
Number of subjects: 191
Study 22442350 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a donor (allo-SCT)
Number of subjects: 260
Study 22442350 — intervention group
Group type: COMPARATOR
Intervention: Patients without a donor (no-allo-SCT)
Number of subjects: 260
Study 22442350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (donor and no-donor)
Number of subjects: 260
Study 22442350 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who proceeded to allo-SCT
Number of subjects: 260
Study 22442350 — intervention group
Group type: COMPARATOR
Intervention: Patients who continued maintenance or received a second high-dose melphalan
Number of subjects: 260
Study 20410834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 336
Study 20410834 — intervention group
Group type: COMPARATOR
Intervention: No PPI
Number of subjects: 336
Study 20410834 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole/Esomeprazole
Number of subjects: 336
Study 18840153 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate allocation concealment
Number of subjects: 35
Study 18840153 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate examiner masking
Number of subjects: 35
Study 18840153 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective power calculation
Number of subjects: 35
Study 18840153 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes in periodontology trials
Number of subjects: 35
Study 15960637 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet received by post 1 week after presurgical assessment (n = 19)
Number of subjects: 40
Study 15960637 — intervention group
Group type: COMPARATOR
Intervention: Leaflet received at presurgical assessment clinic (n = 21)
Number of subjects: 40
Study 15960637 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet received within 2 weeks of surgery (method not specified)
Number of subjects: 40
Study 15960637 — intervention group
Group type: COMPARATOR
Intervention: Both groups (post and clinic delivery)
Number of subjects: 40
Study 12800397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (streptokinase) in community hospitals (Group A)
Number of subjects: 66
Study 12800397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic infusion during transport to PCI center for coronary angioplasty (Group B)
Number of subjects: 66
Study 12800397 — intervention group
Group type: COMPARATOR
Intervention: Primary angioplasty without thrombolysis (Group C)
Number of subjects: 66
Study 10593459 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarming to bladder temperature of 37-38.5 degrees C (group W)
Number of subjects: 38
Study 10593459 — intervention group
Group type: COMPARATOR
Intervention: Rewarming to bladder temperature of 35-37 degrees C (group C)
Number of subjects: 38
Study 8731761 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 57
Study 8731761 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (IVR) 400 micrograms/kg
Number of subjects: 57
Study 8731761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ivermectin (IVR) 400 micrograms/kg and Diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 57
Study 2013676 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (up to 2000 mg)
Number of subjects: 12
Study 2013676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as part of the double-blind design)
Number of subjects: 12
Study 7048338 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg labetalol 3-times daily
Number of subjects: 10
Study 7048338 — intervention group
Group type: COMPARATOR
Intervention: 250 mg alpha‐methyldopa 3-times daily
Number of subjects: 10
Study 31618177 — intervention group
Group type: EXPERIMENTAL
Intervention: ESOB containing phlai oil
Number of subjects: 38
Study 31618177 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 38
Study 29669426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative membership
Number of subjects: 256
Study 29669426 — intervention group
Group type: COMPARATOR
Intervention: Non-membership (Control)
Number of subjects: 256
Study 26831332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven targeted HIV screening combined with current practice (physician-directed diagnostic testing)
Number of subjects: 140000
Study 26831332 — intervention group
Group type: COMPARATOR
Intervention: Current practice alone (physician-directed diagnostic testing)
Number of subjects: 140000
Study 24531816 — intervention group
Group type: EXPERIMENTAL
Intervention: One-shot dilator (group A)
Number of subjects: 100
Study 24531816 — intervention group
Group type: COMPARATOR
Intervention: Telescopic metal dilator (group B)
Number of subjects: 100
Study 22668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) sialogogue
Number of subjects: 35
Study 22668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mechanical/electrical sialogogue
Number of subjects: 35
Study 22668621 — intervention group
Group type: COMPARATOR
Intervention: Mechanical sialogogue
Number of subjects: 35
Study 22668621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 20155644 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17414235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration desipramine (<60 ng/mL)
Number of subjects: 121
Study 17414235 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (benztropine mesylate)
Number of subjects: 121
Study 17414235 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of desipramine (>60 ng/mL)
Number of subjects: 121
Study 17414235 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations of fluoxetine
Number of subjects: 121
Study 15808325 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fish oil (14 g/day)
Number of subjects: 30
Study 15808325 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microM of HHE
Number of subjects: 30
Study 15808325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtures of HHE and HNE
Number of subjects: 30
Study 11953635 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiographs
Number of subjects: 20
Study 11953635 — intervention group
Group type: COMPARATOR
Intervention: Plain radiographs
Number of subjects: 20
Study 9475852 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation of trouser legs
Number of subjects: 16
Study 9475852 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflation of trouser legs and abdominopelvic region
Number of subjects: 16
Study 9475852 — intervention group
Group type: COMPARATOR
Intervention: No trouser inflation (control)
Number of subjects: 16
Study 8593095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulacillin (a combination of sodium ampicillin and sulbactam in a 2:1 ratio)
Number of subjects: 0
Study 2923085 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (900 mg Ca daily)
Number of subjects: 8
Study 2923085 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (CaCl, 900 mg Ca daily)
Number of subjects: 8
Study 2923085 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3, 900 mg Ca daily)
Number of subjects: 8
Study 2923085 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (milk, CaCl, CaCO3)
Number of subjects: 8
Study 337536 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese applicator (27 punctures)
Number of subjects: 0
Study 337536 — intervention group
Group type: COMPARATOR
Intervention: Heaf multipuncture apparatus (40 punctures)
Number of subjects: 0
Study 337536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal method of vaccination
Number of subjects: 0
Study 337536 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese BCG vaccine (percutaneous)
Number of subjects: 0
Study 30170952 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3− (0.3 g.kg−1 body weight)
Number of subjects: 12
Study 30170952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30170952 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3−
Number of subjects: 12
Study 28615070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildipirosin 4 mg/kg, subcutaneously (n = 109)
Number of subjects: 209
Study 28615070 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0.9% saline, subcutaneously (n = 100)
Number of subjects: 209
Study 25959989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART inflammatory markers (CRP, IL-6, D-dimer)
Number of subjects: 1084
Study 23470859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interpretation of stenosis severity
Number of subjects: 175
Study 23470859 — intervention group
Group type: COMPARATOR
Intervention: Quantitative coronary angiography (QCA)
Number of subjects: 175
Study 23470859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical interpretation
Number of subjects: 175
Study 23470859 — intervention group
Group type: COMPARATOR
Intervention: QCA
Number of subjects: 175
Study 21787399 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothes peg pain provocation test
Number of subjects: 157
Study 21787399 — intervention group
Group type: COMPARATOR
Intervention: Electronic pressure algometer
Number of subjects: 157
Study 19567540 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) + Resistance training (RT)
Number of subjects: 107
Study 19567540 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction (CR)
Number of subjects: 107
Study 16514132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal 1 self-etching primer
Number of subjects: 20
Study 16514132 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid etching (37% o-phosphoric acid)
Number of subjects: 20
Study 15235317 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min bout of cycling exercise at approximately 65% of peak oxygen uptake
Number of subjects: 11
Study 15235317 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise condition
Number of subjects: 11
Study 10941877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (0.58 g EPA plus 1.67 g DHA per day)
Number of subjects: 48
Study 10941877 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil supplementation
Number of subjects: 48
Study 10941877 — intervention group
Group type: EXPERIMENTAL
Intervention: Two most concentrated fish oil supplements
Number of subjects: 48
Study 10941877 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 48
Study 10941877 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil and fish oil supplements
Number of subjects: 48
Study 9213798 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferential posture in infants
Number of subjects: 7609
Study 9213798 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants without preferential posture)
Number of subjects: 7609
Study 7966728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bacterial prostatitis
Number of subjects: 106
Study 7966728 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bacterial prostatitis
Number of subjects: 106
Study 7966728 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacterial prostatitis
Number of subjects: 106
Study 3305460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin and cefuroxime
Number of subjects: 52
Study 3305460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 52
Study 30910492 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg orally, once daily 3 times a week for 2 years)
Number of subjects: 89
Study 30910492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 30910492 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 89
Study 30429496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ADR-1
Number of subjects: 68
Study 30429496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ADR-3
Number of subjects: 68
Study 30429496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30429496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ADR-1 and ADR-3
Number of subjects: 68
Study 26938813 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering medication (fixed combination of perindopril and indapamide)
Number of subjects: 11140
Study 26938813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 24215848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to capecitabine monotherapy
Number of subjects: 0
Study 22433778 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of sulphadoxine‐pyrimethamine (SP)
Number of subjects: 1034
Study 22433778 — intervention group
Group type: COMPARATOR
Intervention: Two doses of sulphadoxine‐pyrimethamine (SP)
Number of subjects: 1034
Study 22433778 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester malaria infection
Number of subjects: 1034
Study 22433778 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trimester malaria infection
Number of subjects: 1034
Study 22433778 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester malaria infection (adjusted)
Number of subjects: 1034
Study 22433778 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal anaemia and perinatal mortality
Number of subjects: 1034
Study 18688720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 31
Study 18688720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 59
Study 17227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 59
Study 17227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 59
Study 17227729 — intervention group
Group type: COMPARATOR
Intervention: Control (non-porotic healthy women)
Number of subjects: 59
Study 15296819 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo/desipramine (50 mg)
Number of subjects: 12
Study 15296819 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo/haloperidol (2 mg)
Number of subjects: 12
Study 15296819 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine (50 mg)/haloperidol (2 mg)
Number of subjects: 12
Study 15296819 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine (50 mg)
Number of subjects: 12
Study 15296819 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (2 mg)
Number of subjects: 12
Study 15296819 — intervention group
Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 12
Study 10891977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose creatine (150 mg/kg body weight) followed by low-dose creatine (60 mg/kg)
Number of subjects: 9
Study 9376578 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation (BMT)
Number of subjects: 367
Study 9376578 — intervention group
Group type: COMPARATOR
Intervention: Intensive Consolidation Chemotherapy (ICC)
Number of subjects: 367
Study 9376578 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation (BMT)
Number of subjects: 367
Study 9376578 — intervention group
Group type: COMPARATOR
Intervention: No HLA-identical sibling (control group)
Number of subjects: 367
Study 9376578 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 367
Study 9376578 — intervention group
Group type: COMPARATOR
Intervention: ICC
Number of subjects: 367
Study 1403756 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acetylcholine chloride
Number of subjects: 90
Study 1403756 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% carbachol
Number of subjects: 90
Study 1403756 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 90
Study 4055108 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange and hemodialysis
Number of subjects: 19
Study 4055108 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis
Number of subjects: 19
Study 3579066 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test
Number of subjects: 2842
Study 3579066 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill score of -11 or less
Number of subjects: 2842
Study 3579066 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill score of +7 or more
Number of subjects: 2842
Study 31648883 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-6 levels
Number of subjects: 184305
Study 31648883 — intervention group
Group type: COMPARATOR
Intervention: TC, LDL-C, TG
Number of subjects: 184305
Study 31333778 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy combined with radiotherapy
Number of subjects: 400
Study 28570792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention
Number of subjects: 67
Study 28570792 — intervention group
Group type: COMPARATOR
Intervention: Education program
Number of subjects: 67
Study 28570792 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted group
Number of subjects: 67
Study 26347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpneumatic antishock garment (NASG) added to standard hemorrhage management
Number of subjects: 953
Study 26347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpneumatic antishock garment (NASG)
Number of subjects: 953
Study 24118234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplements during pregnancy
Number of subjects: 738
Study 24118234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplements during pregnancy
Number of subjects: 738
Study 24118234 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for acute lung symptoms in children with recurrent wheeze
Number of subjects: 738
Study 21421766 — intervention group
Group type: EXPERIMENTAL
Intervention: Praying for a stranger
Number of subjects: 0
Study 21421766 — intervention group
Group type: EXPERIMENTAL
Intervention: Praying for the person who angered them
Number of subjects: 0
Study 21421766 — intervention group
Group type: EXPERIMENTAL
Intervention: Praying for a friend in need
Number of subjects: 0
Study 18718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact plus questionnaire
Number of subjects: 560
Study 18718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact only
Number of subjects: 560
Study 18718924 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire only
Number of subjects: 560
Study 18718924 — intervention group
Group type: COMPARATOR
Intervention: Neither
Number of subjects: 560
Study 16507855 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 1010
Study 16507855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010
Study 14504022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine/naloxone
Number of subjects: 89
Study 14504022 — intervention group
Group type: COMPARATOR
Intervention: Lofexidine/placebo
Number of subjects: 89
Study 10709749 — intervention group
Group type: EXPERIMENTAL
Intervention: Exiting using steps and grab-rails
Number of subjects: 10
Study 10709749 — intervention group
Group type: COMPARATOR
Intervention: Exiting from cab-level or trailer-level
Number of subjects: 10
Study 9448971 — intervention group
Group type: EXPERIMENTAL
Intervention: Local data management provision
Number of subjects: 0
Study 8402096 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 16
Study 8402096 — intervention group
Group type: COMPARATOR
Intervention: Plain abdominal radiography
Number of subjects: 16
Study 8402096 — intervention group
Group type: COMPARATOR
Intervention: Abdominal ultrasonography
Number of subjects: 16
Study 8402096 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 16
Study 2937703 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis without PTCA
Number of subjects: 127
Study 2937703 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis with PTCA
Number of subjects: 127
Study 30101329 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB (promotion of breastfeeding, healthy eating, physical activity: 8 contacts, antenatal, 18 mo)
Number of subjects: 802
Study 30101329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep (prevention of sleep problems: antenatal, 3 wk)
Number of subjects: 802
Study 30101329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (both interventions)
Number of subjects: 802
Study 30101329 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 802
Study 26610166 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone treatment for 5 days
Number of subjects: 25